You are here: Industry Insights > BioDelivery

News List

Collegium Purchases BioDelivery Sciences International in All-Cash Deal contractpharma
February 14, 2022
Transaction is valued at $5.60 per share representing a total equity value of $604 million.
BioDelivery Sciences to Acquire U.S. and Canadian Rights to ELYXYB™ for Migraine Treatment americanpharmaceuticalreview
August 05, 2021
BioDelivery Sciences International Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced that it entered into an agreement on August 3, 2021 with Dr. Reddy’s Laboratories ...
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock firstwordpharma
April 11, 2019
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) ("BDSI" or the "Company") today announced that it is ……
BioDelivery Sciences Announces Approval of Bunavail for Opioid Dependence americanpharmaceuticalreview
May 03, 2017
BioDelivery Sciences International announced the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Bunavail (buprenorphine and naloxone) buccal film (CIII)...